What is the most common cancer of the large intestines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common Cancer of the Large Intestines

Adenocarcinoma is the most common cancer of the large intestines, accounting for 95-98% of all colorectal malignancies. 1

Epidemiologic Context

  • Colorectal cancer (CRC) represents the third most common cancer worldwide, accounting for approximately 10% of all tumor types globally, with over 1.1 million new cases annually 1

  • Among colorectal cancers, colon cancer is more frequent than rectal cancer, with a ratio of 2:1 in high-risk populations 1

  • CRC is the second leading cause of cancer death worldwide, with approximately 600,000-930,000 deaths estimated each year 1, 2

Histologic Classification

  • Adenocarcinomas comprise 95-98% of all rectal and colonic malignancies, typically arising from adenomatous polyps through the adenoma-carcinoma sequence 1

  • The remaining 2-5% include rare histologic subtypes such as neuroendocrine tumors, lymphomas, sarcomas, and squamous cell carcinomas (though these are not specifically detailed in the guidelines)

Molecular Pathways

  • The majority of colorectal adenocarcinomas are characterized by chromosomal instability (CIN), which represents the common pathway observed in approximately 85% of cases 1, 3

  • Microsatellite instability (MSI) is rare in rectal cancer (only a few percent) but accounts for approximately 15% of all colorectal cancers, predominantly affecting the right colon 1, 3

  • Key molecular alterations include mutations in the WNT signaling pathway, with APC gene mutations being the most frequent, along with inactivation of tumor suppressor genes (P53, TGFβ pathways) and activation of oncogenes (KRAS, PI3KCA) 1, 4

Clinical Significance

  • Approximately 15-30% of patients present with metastatic disease at diagnosis, and an additional 20-50% of patients with initially localized disease will develop metastases during their disease course 1

  • Colorectal cancer presents as an emergency in approximately 30% of cases, with large bowel obstruction representing 80% of these emergencies (15-30% of all CRC) and perforation accounting for the remaining 20% (1-10% of all CRC) 1, 5

  • The sigmoid colon is the most common site for obstructing colorectal cancer, with approximately 75% of obstructing tumors located distal to the splenic flexure 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Colorectal cancer: Recent advances in management and treatment.

World journal of clinical oncology, 2024

Guideline

Large Bowel Obstruction Causes and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.